Phase 3 pivotal trial assessing CTC-413 for the treatment of Parkinson's Disease
Latest Information Update: 27 Oct 2021
Price :
$35 *
At a glance
- Drugs Pramipexole (Primary)
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Chase Therapeutics
- 27 Oct 2021 New trial record
- 20 Oct 2021 According to Chase Therapeutics media release, the completion of a milestone based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong will support this trial